Universidad San Carlos

Recent papers from Universidad San Carlos

1. Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI TrialJournal of the American Heart Association · 2026
2. Training through trauma: A multivariate analysis of burnout and associated factors among physician trainees in Guatemala.Psychological Trauma Theory Research Practice and Policy · 2026
3. Techno(geo)politics of erasure: visibility, violence and the digital battlefield of PalestineThird World Quarterly · 2026
4. Association between patient-reported symptoms and clinical outcomes in R/R CLLBlood Advances · 2026
5. Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial CancerClinical Pharmacology & Therapeutics · 2026
6. Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparisonJournal of Comparative Effectiveness Research · 2026
7. Engineered antibodies preserve structural and functional recognition of Plasmodium falciparum circumsporozoite proteinProtein Science · 2026
8. Analysis of gene co-expression connectivity dynamics implicates aberrant neuron-oligodendroglia interactions in schizophreniaNature Communications · 2026
9. Recombinant polyclonal antibody GIGA-2339 potently and pan-genotypically neutralizes hepatitis B virusAntiviral Research · 2026
10. Alzheimer’s disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPAScience Translational Medicine · 2026
11. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase InhibitorJournal of Clinical Oncology · 2026
12. Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsBlood Advances · 2026
13. Evaluating the Impact of Enfortumab Vedotin Dose Modifications on Clinical Efficacy Using Tumor Growth Inhibition Modeling in Patients With Advanced Urothelial CancerThe Journal of Clinical Pharmacology · 2026
14. Setting Priorities for the Acquisition of Primary Plant Occurrence DataDiversity and Distributions · 2026
15. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti–PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or MoreJournal of Thoracic Oncology · 2026
16. Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLLOncology and Therapy · 2026
17. Prognostic associations between patient-reported outcomes and overall survival among patients with advanced squamous non-small cell lung cancer: results from the RATIONALE-307 trialQuality of Life Research · 2026
18. Ensilication preserves high-molecular weight native DNA for clinical long-read sequencingGenome biology · 2026
19. Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-UpAdvances in Therapy · 2026
20. Structure and functional diversity of antibodies targeting the P. falciparum circumsporozoite protein C-terminal domain2026